Natalie Dolphin brings over 15 years of experience in marketing, business development, and capital markets. Over the years, Natalie has held managerial roles at several private and public companies as well as the Canadian Securities Exchange (CSE), where she facilitated companies going public and assisted with series A and B funding opportunities.
As the VP of Marketing & Investment Relations at Wellbeing Digital Sciences, and formerly the Director of Marketing at MagicMed Industries (acquired by Nasdaq-listed Enveric Biosciences Inc.), Natalie has demonstrated her expertise in raising capital. In Q1 2024 alone, she raised $6.7M USD for HLTH clients. Her career reflects strong capabilities in driving business growth and securing investment, showcasing her proficiency in both strategic marketing and financial stewardship.
Discover all you need to know about stealth mode biotech startups, including what stealth mode is and its advantages and disadvantages.
Biotech and healtcare contributed to more than one out of three megadeals in 2024. Find out the reasons behind it.
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list of some of the top executives in the space to keep an eye on.
”Investors’ increased focus on health and biotech startups is driven by technological advancements such as AI in drug discovery, the heightened awareness of healthcare innovation post-pandemic, and supportive regulatory environments. Additionally, the aging global population and the significant focus on longevity are fueling interest in these areas, as they promise long-term impact and resilience.”